Lineage Ebit from 2010 to 2024

LCTX Stock  USD 0.57  0.04  6.56%   
Lineage Cell EBIT yearly trend continues to be fairly stable with very little volatility. EBIT will likely drop to about -26 M in 2024. During the period from 2010 to 2024, Lineage Cell EBIT regression line of annual values had significance of  0.96 and arithmetic mean of (41,652,795). View All Fundamentals
 
EBIT  
First Reported
1994-06-30
Previous Quarter
-5.9 M
Current Value
-3.8 M
Quarterly Volatility
16.7 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 9.4 M, as well as many indicators such as Price To Sales Ratio of 19.99, Dividend Yield of 0.0015 or PTB Ratio of 3.12. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.
  
Check out the analysis of Lineage Cell Correlation against competitors.

Latest Lineage Cell's Ebit Growth Pattern

Below is the plot of the Ebit of Lineage Cell Therapeutics over the last few years. It is Lineage Cell's EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.
Ebit10 Years Trend
Very volatile
   Ebit   
       Timeline  

Lineage Ebit Regression Statistics

Arithmetic Mean(41,652,795)
Coefficient Of Variation(82.39)
Mean Deviation23,192,936
Median(27,827,253)
Standard Deviation34,319,456
Sample Variance1177.8T
Range146.4M
R-Value(0.01)
Mean Square Error1268.2T
R-Squared0.0002
Significance0.96
Slope(97,660)
Total Sum of Squares16489.6T

Lineage Ebit History

2024-26 M
2023-24.7 M
2022-22.5 M
2021-49.2 M
2020-26.5 M
2019-38.9 M
2018-35.5 M

Other Fundumenentals of Lineage Cell Therapeutics

About Lineage Cell Financial Statements

Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBIT-24.7 M-26 M
EBITDA-24 M-25.2 M
Ebt Per Ebit 0.94  0.98 
Ebit Per Revenue(2.77)(2.90)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.